Humog 150 Injection contains Menotrophin 150 IU, a purified preparation of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) derived from the urine of postmenopausal women. It is indicated for the treatment of infertility in both male and female patients by stimulating follicular development in women and spermatogenesis in men. In females, Humog 150 is primarily used to induce ovulation in anovulatory women who do not respond to clomiphene citrate and to promote multifollicular development in assisted reproductive technologies such as in vitro fertilization (IVF). In males, it is employed to stimulate spermatogenesis in cases of hypogonadotropic hypogonadism. The administration of Humog 150 should be carefully monitored by a healthcare professional experienced in fertility treatments, with dosage individualized based on patient response and follicular development assessed via ultrasound and hormone levels. Common adverse effects include ovarian hyperstimulation syndrome (OHSS), injection site reactions, and multiple pregnancies. Contraindications include primary ovarian failure, uncontrolled thyroid or adrenal dysfunction, and hormone-dependent tumors. Humog 150 Injection must be used under strict medical supervision to optimize efficacy and minimize risks associated with gonadotropin therapy.